Leishmaniasis

Nonprofit pharmaceutical seeks drug approval next year

Published in TB and Outbreaks Week, February 17th, 2004

The Institute for OneWorld Health, a nonprofit pharmaceutical company, has announced that it is only a year away from seeking approval for its first medicine, a drug to cure a deadly parasitic disease in India.

The announcement came from Founder and CEO Victoria Hale, PhD. Hale was invited to speak at the World Economic Forum in Davos, Switzerland, as a panelist in a roundtable discussion, "Winning the All-Fronts War against AIDS." While at the international meeting, Hale announced OneWorld Health's intention to bring paromomycin to market in India in the next year.

Paromomycin is a treatment for visceral leishmaniasis (VL), also known as kala azar....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2004-02-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry